Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
Jian-Qing MiWanhong ZhaoHongmei JingWeijun FuJianda HuLijuan ChenYiwen ZhangDan YaoDiana ChenJordan M SchecterFan YangXiaochen TianHuabin SunSen Hong ZhuangJimmy RenXiaohu FanJie JinTing NiuSai-Juan ChenPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
These data demonstrate a favorable risk-benefit profile for a single infusion of cilta-cel, resulting in early, deep, and durable responses in heavily pretreated patients with RRMM in China.
Keyphrases
- phase ii
- open label
- cell therapy
- multiple myeloma
- clinical trial
- phase iii
- stem cells
- phase ii study
- acute myeloid leukemia
- mesenchymal stem cells
- study protocol
- placebo controlled
- double blind
- low dose
- diffuse large b cell lymphoma
- big data
- randomized controlled trial
- squamous cell carcinoma
- radiation therapy
- data analysis